Poor
Not Aligned
Patient Risk:
High
Summary
Multiple specific sleep-cycle/circadian rhythm and downstream consequence claims are not supported by the provided FDA label excerpts. Only somnolence/dizziness warnings are reasonably supported (5.5), and several mechanisms/outcomes are introduced without label support, leading to a poor overall alignment.
Category Scores
Accurate Statements
Lyrica may cause dizziness and somnolence, which can impair tasks such as driving or operating machinery.
5.5 Dizziness and Somnolence
Lyrica binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues.
12.1 Mechanism of Action
Unsupported Statements
Lyrica (pregabalin) is a central nervous system depressant.
No provided label excerpt characterizes pregabalin as a 'central nervous system depressant' (only mechanism binding and somnolence/dizziness are provided).
Lyrica works by binding to specific receptors in the brain.
Label support is for binding to the alpha2-delta site in central nervous system tissues, but provided excerpt does not support the phrasing 'in the brain' or 'receptors' as stated.
Lyrica reduces the release of neurotransmitters that contribute to pain and anxiety.
Label excerpt supports reduction of calcium-dependent release of pro-nociceptive neurotransmitters in the spinal cord and possible descending pathway modulation; it does not mention 'anxiety' or match the claim wording.
Research suggests that Lyrica can disrupt the normal sleep cycle.
No provided label excerpt discusses disruption of a 'sleep cycle' or sleep-cycle physiology.
Lyrica can lead to changes in sleep duration, quality, and timing.
No provided label excerpt discusses sleep duration/quality/timing.
A study reported that patients taking Lyrica experienced significant improvements in sleep quality.
No provided label excerpt includes clinical-study outcomes for improved sleep quality.
The same study reported increased daytime sleepiness and fatigue in patients taking Lyrica.
Label excerpt supports somnolence; it does not explicitly support 'daytime' or 'fatigue' as stated.
Lyrica can cause temporary changes in sleep patterns.
No provided label excerpt describes changes in 'sleep patterns.'
Some users have reported experiencing a permanent shift in their sleep cycle while taking Lyrica.
No provided label excerpt discusses permanent sleep-cycle shifts or user-reported outcomes.
A permanent shift in the sleep-wake cycle is known as a circadian rhythm disorder.
No provided label excerpt defines circadian rhythm disorders.
Circadian rhythm disorders occur when the body's internal clock is disrupted, leading to changes in the timing of sleep and wakefulness.
No provided label excerpt provides this definition.
A permanent shift in the sleep cycle can cause impaired cognitive function.
No provided label excerpt links sleep-cycle/circadian changes to cognitive impairment.
A permanent shift in the sleep cycle can cause mood disturbances.
No provided label excerpt links sleep-cycle/circadian changes to mood disturbances.
A permanent shift in the sleep cycle can increase the risk of accidents due to excessive daytime sleepiness.
No provided label excerpt ties 'permanent shift/circadian rhythm disorder' to accident risk; the closest label statement is general impairment of driving/operating machinery due to dizziness/somnolence (5.5).
An expert stated that Lyrica can cause significant changes in sleep patterns, including a permanent shift in the sleep-wake cycle.
No provided label excerpt contains 'expert' statements or supports persistent/permanent sleep-wake-cycle change.
An expert stated that a permanent shift in the sleep-wake cycle from Lyrica can have serious consequences for daily life, including impaired cognitive function and mood disturbances.
No provided label excerpt supports this causal narrative or the linked consequences.
Contradictions
Important Omissions
If sleep-cycle/circadian disruption is discussed, the response omits reliance on (and does not cite) any specific FDA label language supporting these effects; instead it asserts permanent circadian-related outcomes.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The claims introduce specific, permanent circadian/sleep-cycle disruption and downstream outcomes (cognitive impairment, mood disturbances, accident risk) without support in the provided FDA label excerpts. Even though somnolence/dizziness is label-supported, the unlabelled permanence and downstream consequences increase the risk of misinformation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Unsubstantiated (by the provided label excerpts) claims about permanent sleep-cycle/circadian rhythm disorders and downstream cognitive/mood/accident consequences.
Suggested Improvement
Remove or heavily qualify all circadian/permanent sleep-cycle and associated cognitive/mood/accident narrative unless the exact supporting FDA label text is provided; restrict sleep-related claims to label-supported dizziness/somnolence and the associated functional warning about driving/operating machinery (5.5).